#Canada #Mississauga #Septa Pharmaceuticals #CeeNU #lomustine

Septa Pharmaceuticals Expands Oncology Portfolio with CeeNU® Acquisition

On June 29, 2026, Septa Pharmaceuticals Inc., a prominent name in the Canadian healthcare sector, announced the acquisition of CeeNU®, a well-established chemotherapy drug primarily used for treating specific types of brain tumors and Hodgkin's lymphoma. This significant move marks a milestone in Septa's strategy to broaden its specialty oncology pharmaceutical offerings.

The acquisition of CeeNU® (Lomustine), developed by Bristol Myers Squibb, represents a consolidation of Septa's commitment to improving patient health outcomes through innovative treatments. As an alkylating agent, Lomustine plays a critical role in cancer therapy. The integration of CeeNU® into Septa's product portfolio not only enhances the range of treatments available to patients but also reinforces the company's position in a highly competitive oncology market.

President and CEO of Septa Pharmaceuticals, Devinder K., stated, "As we incorporate CeeNU® into our expanding portfolio, we prioritize the needs of patients and healthcare professionals alike. Our collaboration with regulatory bodies and supply chain partners aims to facilitate a smooth transition and ensure the sustained availability of this essential medication across Canada."

With a patient-first philosophy, Septa Pharmaceuticals acknowledges the escalating demand for stable and reliable access to critical medications amidst a complex healthcare landscape. The commitment to long-term supply planning for CeeNU® echoes the company’s understanding of the healthcare system’s intricacies and the importance of supporting those who are battling severe health conditions.

Septa's strategic aspirations include not only the management of its existing products but also the pursuit of new partnerships and licensing opportunities that can further enhance its impact in global markets. "We are eager to collaborate with other pharmaceutical organizations to launch and commercialize high-impact therapies that are essential to healthcare", remarked Devinder K.

Septa Pharmaceuticals, headquartered in Ontario, Canada, is dedicated to the ongoing development, acquisition, and commercialization of specialized pharmaceuticals. By bridging gaps in the healthcare sector with innovative solutions and steady supply, Septa plays a vital role in supporting the medical community.

The acquisition of CeeNU® is not just a business strategy for Septa; it represents a critical step towards fulfilling their mission to provide accessible, quality healthcare solutions to the wider community. By expanding their portfolio and integrating vital medications like CeeNU®, Septa Pharmaceuticals Inc. is poised for sustained growth and enhanced capability in delivering lifesaving treatments to patients in need.

As Septa continues to navigate the complexities of the healthcare environment, its dedication to patient-centric care and the strategic management of its pharmaceuticals will drive its future success. The company remains optimistic about its trajectory and committed to its goal of improving health outcomes on both local and global stages.